Role of Real-World Evidence in the Evolving Treatment Landscape of Multiple Myeloma

Muhamed Baljević, MD, FACP, provides a background of multiple myeloma (MM) within the past five years and the main treatment options.

Joshua Richter, MD, and Roy Beveridge, MD, explain the role triplet regimens play in MM treatment and how physician decision-making has been impacted since the NCCN guidelines have expanded the list of acceptable first- and second-line treatment options.

Dr Beveridge provides a payer’s perspective on the available regimens for MM treatment.

The panel discusses the data used to evaluate healthcare resources for MM therapy, as well as economic burden.

A panel of experts elaborate on the decision support tools that are utilized by physicians to give patients high-value regimens.

Dr Baljević explain some of the limitations physicians can come across with applying randomized clinical trial (RCT) data to MM treatment.

Dr Richter relays some of the differences between real-world evidence (RWE) and RCT data, as well as how they can work together when determining therapy.

Jay Weaver, PharmD, MPH, and Muhamed Baljević, MD, FACP, discuss how RWE can affect the management of MM.

The panel elaborate on how they’ve incorporated RWE into their decision-making processes for their patients with MM.

Dr Beveridge explains potential barriers a physician can encounter when implementing RWE into MM therapy.

The panel moves the discussion to non-comparative RWE and how that can play a part in their decision-making for MM therapy.

Dr Richter delves into how we can better educate patients and physicians on RWE to improve decision-making.

Dr Baljević discusses unmet needs that are typically seen in the management of MM.

Our panel concludes with their plans to incorporate RWE into MM management in the future.